Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Photodynamic Therapy in Refractory Mycosis Fungoides: A Prospective, Open-Label Study

Caitlin M Brumfiel, M.S., Kevin J Severson, B.A., Meera H Patel, B.S., Helen J L Cumsky, MD, Brenda F Ginos, B.A., Heidi E. Kosiorek, MS, Monica C Janeczek, MD, Jake Besch-Stokes, B.S., William Rule, MD, David DiCaudo, MD, Allison C. Rosenthal, D.O., Mark R Pittelkow, MD, Aaron R Mangold, MD

Blood (2020) 136 (Supplement 1): 32.

https://doi.org/10.1182/blood-2020-141119

Published: 2020

Journal Articles

Impact of COVID19 Pandemic on an International MPN Patient Population: Survey Results from 1560 MPN Patients

Blood (2020) 136 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2020-138953

Published: 2020

Journal Articles

Relationship of Area-Level Socioeconomic Status Indicators and Nutritional Anemias: Analysis of Folate, Vitamin B12, and Iron Deficiencies

Miguel Gonzalez Velez, MD, Carolyn Mead-Harvey, MS, Heidi E. Kosiorek, MS, Yael Kusne, MD PhD, Leyla Bojanini, MD, Candido E. Rivera, MD, Donald Northfelt, MD, Chung-II Wi, MD, Leslie Padrnos, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-142897

Published: 2020

Journal Articles

Rationale for and Results of a Phase I Study of the TGF-β 1/3 Inhibitor AVID200 in Subjects with Myelofibrosis: MPN-RC 118 Trial

John Mascarenhas, MD, Heidi E. Kosiorek, MS, Lilian Varricchio, PhD, Rupali Bhave, MD, Andrew T. Kuykendall, MD, Rami Komrokji, MD, Aaron T. Gerds, MDMS, Jeanne M. Palmer, MD, Amelia R. Gabler, Lonette Sandy, Anna Rita Migliaccio, PhD, Mohamed E Salama, MD, Rona Singer Weinberg, PhD, Maureen O'Connor-McCourt, PhD, Gilles Tremblay, PhD, Paul I. Nadler, MD, Amylou C. Dueck, PhD, Ruben A. Mesa, MD FACP, Ronald Hoffman, MD

Blood (2020) 136 (Supplement 1): 6–8.

https://doi.org/10.1182/blood-2020-140830

Published: 2020

Journal Articles

Analysis of Free-Text Responses in an International Myeloproliferative Neoplasms Patient Survey to Assess Impact of the COVID-19 Pandemic on Clinical Care

Blake T. Langlais, MS, Carolyn Mead-Harvey, MS, Heidi E. Kosiorek, MS, Gina L. Mazza, PhD, Ruben Mesa, MD, Jeanne M. Palmer, MD, Amylou C. Dueck, PhD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-143172

Published: 2020

Journal Articles

Ropeginterferon Demonstrates Safety and Efficacy in Myelofibrosis: Pilot Study Results

Jeanne M. Palmer, MD, Heidi E. Kosiorek, MS, Amylou C. Dueck, PhD, John Camoriano, MD, Craig Zimmerman, PhD, Ruben Mesa, MD

Blood (2020) 136 (Supplement 1): 23.

https://doi.org/10.1182/blood-2020-138934

Published: 2020

Journal Articles

Symptom Burden and Quality of Life in High-Risk Essential Thrombocythemia and Polycythemia Vera Patients Receiving Hydroxyurea or Pegylated Interferon Alfa-2a: Results of Myeloproliferative Neoplasms Research Consortium (MPN-RC) 111 and 112 Trials

Gina L. Mazza, PhD, Carolyn Mead-Harvey, MS, John Mascarenhas, MD, Abdulraheem Yacoub, MD, Ronald Hoffman, MD, Heidi E. Kosiorek, MS, Josef T. Prchal, MD, Richard T. Silver, MD, Tiziano Barbui, MD, Amylou C. Dueck, PhD, Ruben Mesa, MD

Blood (2020) 136 (Supplement 1): 19–21.

https://doi.org/10.1182/blood-2020-142817

Published: 2020

Journal Articles

Clinical Trial Design Features of Myelofibrosis Trials during the Last Decade: Comprehensive Review of Clinicaltrials.Gov Data 2010-2019

Heidi E. Kosiorek, MS, Amylou C. Dueck, PhD, John Mascarenhas, MD, Ruben A. Mesa, MD FACP, Ronald Hoffman, MD, Blake T. Langlais, MS

Blood (2020) 136 (Supplement 1): 37.

https://doi.org/10.1182/blood-2020-137809

Published: 2020

Journal Articles

Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS)

Blake T. Langlais, MS, Heidi E. Kosiorek, MS, Gina L. Mazza, PhD, Carolyn Mead-Harvey, MS, Richard Butterfield, III, Jeanne M. Palmer, MD, Ruben Mesa, MD, Amylou C. Dueck, PhD

Blood (2020) 136 (Supplement 1): 26.

https://doi.org/10.1182/blood-2020-142838

Published: 2020

Journal Articles

Improving the Definition of Response Assessment: Prognostic Value of Minimal Residual Disease Combined with PET/CT at Day 100 Post Autologous Stem Cell Transplantation in Multiple Myeloma

Miguel Gonzalez-Velez, MD, Mariano Arribas, Heidi E. Kosiorek, MS, Richard Butterfield, III, Carlo Guerrero, MD, Luke Mountjoy, DO, Jeremy Larsen, Craig B. Reeder, MD, P. Leif Bergsagel, MD, A. Keith Stewart, MB, ChB, Rafael Fonseca, MD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-142845

Published: 2020

Journal Articles

Symptom Burden in "Low Risk PV" Frequently Is Problematic and May Justify Earlier Intervention with Cytoreductive Therapy: An MPN-QOL Study Group Study

Ruben Mesa, MD, Heidi E. Kosiorek, MS, Alessandra Carobbio, BSc, Tiziano Barbui, MD, Amylou C. Dueck, PhD

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-134583

Published: 2020

Journal Articles

Identifying Cytokine Biomarkers of Response to Pegylated-Interferon Therapy in Polycythemia Vera and Essential Thrombocythemia: Correlative Analysis from the MPN-RC 111/112 Trials

Andrew Dunbar, MD, Heidi E. Kosiorek, MS, Aishwarya Krishnan, Erin McGovern, BA, Young Park, BS, Minal A Patel, MPH, Rona Singer Weinberg, PhD, Abdulraheem Yacoub, MD, Amylou C. Dueck, PhD, John Mascarenhas, MD, Ross L. Levine, MD, Ronald Hoffman, MD, Raajit K. Rampal, MD PhD

Blood (2019) 134 (Supplement_1): 1661.

https://doi.org/10.1182/blood-2019-129571

Published: 2019

Journal Articles

Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings

Blood (2019) 134 (Supplement_1): 2943.

https://doi.org/10.1182/blood-2019-124865

Published: 2019

Journal Articles

Significance of Abnormalities of PPM1D in Myeloproliferative Neoplasms

Bridget Marcellino, MD PhD, Joseph Tripodi, Michal Bar-Natan, MD, Harry Fruchtman, Noushin Farnoud, PhD, Min Lu, PhD, Heidi E. Kosiorek, MS, Amylou C. Dueck, PhD, Raajit K. Rampal, MD PhD, John Mascarenhas, MD, Vesna Najfeld, PhD, Ronald Hoffman, MD

Blood (2019) 134 (Supplement_1): 4207.

https://doi.org/10.1182/blood-2019-129565

Published: 2019

Journal Articles

Racial Differences in Nutritional Anemias: Analysis of Folate, Vitamin B12, and Iron Deficiencies

Miguel Gonzalez Velez, MD, Carolyn Mead-Harvey, MS, Heidi E. Kosiorek, MS, Yael Kusne, MD PhD, Leslie Padrnos, MD

Blood (2019) 134 (Supplement_1): 3387.

https://doi.org/10.1182/blood-2019-123791

Published: 2019

Journal Articles

Expansion of Prior Existing TP53 Mutated Clones in Polycythemia Vera Patients Treated with Idasanutlin

Bridget Marcellino, MD PhD, Bruno Cassinat, PharmD, PhD, Noushin Farnoud, PhD, Min Lu, PhD, Emmanuelle Verger, PhD, Erin McGovern, BA, Minal A Patel, MPH, Heidi E. Kosiorek, MS, Meenakshi Mehrotra, PhD, Jane Houldsworth, PhD, Amylou C. Dueck, PhD, Michael Rossi, PhD, Jean-Jacques Kiladjian, MD PhD, Raajit K. Rampal, MD PhD, John Mascarenhas, MD, Ronald Hoffman, MD

Blood (2019) 134 (Supplement_1): 838.

https://doi.org/10.1182/blood-2019-128342

Published: 2019

Journal Articles

Utilization of Patient-Reported Outcomes in Myeloproliferative Neoplasm Clinical Trials Registered at Clinicaltrials.Gov

Blake T. Langlais, Gina Mazza, PhD, Crystal S. Langlais, MPH, Heidi E. Kosiorek, MS, Holly L. Geyer, MD, Ruben A. Mesa, MD, Robyn M. Scherber, MD MPH, Amylou C. Dueck, PhD

Blood (2018) 132 (Supplement 1): 5469.

https://doi.org/10.1182/blood-2018-99-117446

Published: 2018

Journal Articles

Clinical Benefit of Ropeginterferon Alfa 2b (P1101) in Patients with Myelofibrosis

Jeanne Palmer, MD, Heidi E. Kosiorek, MS, Craig Zimmerman, PhD, Oleh Zagrijtschuk, MD, John Camoriano, MD, Ruben A. Mesa, MD

Blood (2018) 132 (Supplement 1): 5475.

https://doi.org/10.1182/blood-2018-99-115521

Published: 2018

Journal Articles

Assessment of Quality of Life Following Allogeneic Stem Cell Transplant for Myelofibrosis

Jeanne Palmer, MD, Heidi E. Kosiorek, MS, Christine Wolschke, MD, Veena D. S. Fauble, MD, Richard Butterfield, III, Holly Geyer, MD, Robyn M. Scherber, MD, Amylou C. Dueck, PhD, Allison Gathany, MD, Ruben A. Mesa, MD FACP, Nicolaus Kroeger, MD

Blood (2018) 132 (Supplement 1): 4827.

https://doi.org/10.1182/blood-2018-99-111420

Published: 2018

Journal Articles

Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)

Blood (2018) 132 (Supplement 1): 577.

https://doi.org/10.1182/blood-2018-99-111946

Published: 2018

NARROW

Photodynamic Therapy in Refractory Mycosis Fungoides: A Prospective, Open-Label Study

Impact of COVID19 Pandemic on an International MPN Patient Population: Survey Results from 1560 MPN Patients

Relationship of Area-Level Socioeconomic Status Indicators and Nutritional Anemias: Analysis of Folate, Vitamin B12, and Iron Deficiencies

Rationale for and Results of a Phase I Study of the TGF-β 1/3 Inhibitor AVID200 in Subjects with Myelofibrosis: MPN-RC 118 Trial

Analysis of Free-Text Responses in an International Myeloproliferative Neoplasms Patient Survey to Assess Impact of the COVID-19 Pandemic on Clinical Care

Ropeginterferon Demonstrates Safety and Efficacy in Myelofibrosis: Pilot Study Results

Symptom Burden and Quality of Life in High-Risk Essential Thrombocythemia and Polycythemia Vera Patients Receiving Hydroxyurea or Pegylated Interferon Alfa-2a: Results of Myeloproliferative Neoplasms Research Consortium (MPN-RC) 111 and 112 Trials

Clinical Trial Design Features of Myelofibrosis Trials during the Last Decade: Comprehensive Review of Clinicaltrials.Gov Data 2010-2019

Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS)

Improving the Definition of Response Assessment: Prognostic Value of Minimal Residual Disease Combined with PET/CT at Day 100 Post Autologous Stem Cell Transplantation in Multiple Myeloma

Symptom Burden in "Low Risk PV" Frequently Is Problematic and May Justify Earlier Intervention with Cytoreductive Therapy: An MPN-QOL Study Group Study

Identifying Cytokine Biomarkers of Response to Pegylated-Interferon Therapy in Polycythemia Vera and Essential Thrombocythemia: Correlative Analysis from the MPN-RC 111/112 Trials

Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings

Significance of Abnormalities of PPM1D in Myeloproliferative Neoplasms

Racial Differences in Nutritional Anemias: Analysis of Folate, Vitamin B12, and Iron Deficiencies

Expansion of Prior Existing TP53 Mutated Clones in Polycythemia Vera Patients Treated with Idasanutlin

Utilization of Patient-Reported Outcomes in Myeloproliferative Neoplasm Clinical Trials Registered at Clinicaltrials.Gov

Clinical Benefit of Ropeginterferon Alfa 2b (P1101) in Patients with Myelofibrosis

Assessment of Quality of Life Following Allogeneic Stem Cell Transplant for Myelofibrosis

Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only